The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of obesity in patients with metastatic urothelial carcinoma.
 
Amanda Leiter
No Relationships to Disclose
 
John Doucette
No Relationships to Disclose
 
Susanne Krege
No Relationships to Disclose
 
Chia-Chi Lin
No Relationships to Disclose
 
Noah M. Hahn
Honoraria - D3 Oncology Solutions
Speakers' Bureau - Medivation
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dendreon (Inst); Fluidigm (Inst); Genentech/Roche (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bionomics; Millennium
 
Thorsten Ecke
No Relationships to Disclose
 
Guru Sonpavde
No Relationships to Disclose
 
Aristotelis Bamias
No Relationships to Disclose
 
William K. Oh
Honoraria - Active Biotech; Amgen; Bayer; Bellicum Pharmaceuticals; Dendreon; Janssen Biotech; Medivation; OncoCellMDx; Pfizer; Sanofi; Xcenda
Research Funding - Millennium (Inst)
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck